摘要
人细小病毒B19(HPVB19)属细小病毒科,红细胞病毒属,与多种人类疾病相关,HPVB19感染是异基因造血干细胞移植(allo-HSCT)后难治性贫血的重要原因之一.此项研究对24例HSCT合并HPVB19感染的患者进行了回顾性分析,旨在整理总结allo-HSCT术后合并HPVB19感染患者的临床表现、治疗与转归,为allo-HSCT后HPVB19感染的管理提供经验.HPVB 19感染患者中位年龄为25岁,感染发生的中位时间为移植后107d(+107d),有22例(91.7％)患者存在贫血,HGB中位数为77.5(46～149)g/L;新发贫血或血红蛋白持续下降的患者有13例(54.2％).患者的中位住院时长为19 d,在新发贫血或HGB持续下降的患者中,经过静脉丙种球蛋白和(或)抗病毒治疗后HGB平均升高15.69 g/L,10例(76.92％)患者治疗有效.HSCT后出现难治性贫血时应警惕HPVB 19感染;尽管缺乏特异性的治疗手段,HPVB19感染患者总体预后较好.
Abstract
Human parvovirus B19(HPVB19)belongs to Parvoviridae,a genus of erythrovirus,and has been associated with various human diseases,and HPVB19 infection is one of the most important causes of refractory anemia after allogeneic hematopoietic stem cell transplantation(allo-HSCT).This study retrospectively analyzed 24 patients with HSCT combined with HPVB19 infection to collate and summarize the clinical presentation,treatment,and regression of patients with combined HPVB19 infection after allo-HSCT and provide experience in the management of HPVB19 infection after allo-HSCT.The median age of the patients with HPVB19 infection was 25 years,and the median time of infection occurrence was+107 days after transplantation,and 22(91.7％)had anemia with a median hemoglobin(HGB)level of 77.5(46-149)g/L,and 13(54.2％)had new-onset anemia or persistent decline in HGB.The median length of hospital stay was 19 days.Among patients with new-onset anemia or persistent decline in HGB,the mean increase in HGB after treatment with intravenous immunoglobulin and/or antiviral therapy was 15.69 g/L,and treatment was effective in 10(76.92％)patients.HPVB19 infection should be alerted to the development of refractory anemia after HSCT;despite the lack of specific treatment,the overall prognosis of HPVB19-infected patients is good.
基金项目
国家自然科学基金(8227010768)
科技部重点研发计划(2021YFC2500300)
NETL
NSTL
万方数据